We just got tipped off about layoffs at Forma Therapeutics yesterday. Staffers tell us that 25 people in discovery biology got the ax, with execs attributing the cuts to issues involving their pact with Celgene. CEO Steve Tregay confirmed that there have been cuts, adding that they are part of a broader reorganization that is claiming 61 jobs at the company.
But Tregay declined to say anything about the Celgene relationship, which is a cornerstone of the Watertown, MA-based company.
According to Steve Tregay:
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,000+ biopharma pros who read Endpoints News by email every day.Free Subscription